DK1592793T3 - Oligomeriske forbindelser for modulation af Survivin ekspression - Google Patents

Oligomeriske forbindelser for modulation af Survivin ekspression

Info

Publication number
DK1592793T3
DK1592793T3 DK04709580T DK04709580T DK1592793T3 DK 1592793 T3 DK1592793 T3 DK 1592793T3 DK 04709580 T DK04709580 T DK 04709580T DK 04709580 T DK04709580 T DK 04709580T DK 1592793 T3 DK1592793 T3 DK 1592793T3
Authority
DK
Denmark
Prior art keywords
modulation
oligomeric compounds
survivin expression
survivin
expression
Prior art date
Application number
DK04709580T
Other languages
Danish (da)
English (en)
Inventor
Majken Westergaard
Margit Wissenbach
Jens Bo Rode Hansen
Charlotte Albaek Thrue
Kamille Dumong Petersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32852145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1592793(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1592793T3 publication Critical patent/DK1592793T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
DK04709580T 2003-02-10 2004-02-10 Oligomeriske forbindelser for modulation af Survivin ekspression DK1592793T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300183 2003-02-10
DKPA200301708 2003-11-18
PCT/DK2004/000096 WO2004069991A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of survivin expression

Publications (1)

Publication Number Publication Date
DK1592793T3 true DK1592793T3 (da) 2009-10-26

Family

ID=32852145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04709580T DK1592793T3 (da) 2003-02-10 2004-02-10 Oligomeriske forbindelser for modulation af Survivin ekspression

Country Status (10)

Country Link
EP (1) EP1592793B2 (de)
JP (3) JP4503590B2 (de)
AU (1) AU2004209598B2 (de)
CA (1) CA2515623A1 (de)
DE (1) DE602004022020D1 (de)
DK (1) DK1592793T3 (de)
ES (1) ES2329131T3 (de)
MX (1) MXPA05008319A (de)
PT (1) PT1592793E (de)
WO (1) WO2004069991A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2264172T (pt) 2002-04-05 2017-12-06 Roche Innovation Ct Copenhagen As Compostos oligoméricos para a modulação da expressão do hif-1α.
DK2752488T3 (da) 2002-11-18 2020-04-20 Roche Innovation Ct Copenhagen As Antisense-design
WO2004069991A2 (en) * 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
PL1763356T3 (pl) * 2004-04-22 2008-12-31 Lilly Co Eli Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
AU2005304110B2 (en) * 2004-11-09 2009-06-11 Enzon Pharmaceuticals, Inc. LNA oligonucleotides and the treatment of cancer
ES2353638T3 (es) * 2004-11-09 2011-03-03 Santaris Pharma A/S Oligonucleótidos de lna y el tratamiento del cáncer.
NZ555644A (en) 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
EP3502255A1 (de) 2006-04-03 2019-06-26 Roche Innovation Center Copenhagen A/S Pharmazeutische zusammensetzung
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2092065B2 (de) 2006-10-18 2019-07-24 Ionis Pharmaceuticals, Inc. Antisense-verbindungen
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
EP2126079A1 (de) 2007-03-22 2009-12-02 Santaris Pharma A/S Rna-antagonistenverbindungen zur hemmung der apo-b100-expression
EP2623599B1 (de) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Mikromir-Moleküle
JP2009171895A (ja) * 2008-01-24 2009-08-06 Hitachi Software Eng Co Ltd 核内ノンコーディングｒｎａの機能解析方法
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
WO2010017311A2 (en) * 2008-08-05 2010-02-11 Mdrna, Inc. Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
DE102011100581A1 (de) 2011-05-04 2012-11-08 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von hyperproliferativen Erkrankungen des Urogenitaltraktes
EP2742135B2 (de) 2011-08-11 2020-06-10 Ionis Pharmaceuticals, Inc. Rückgratmodifizierte gapmer verbindungen und ihre verwendungen
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
EP3004347B1 (de) * 2013-05-30 2018-09-26 National University Corporation Tokyo Medical and Dental University Doppelsträngige mittel zur verabreichung therapeutischer oligonukleotide
PT3013959T (pt) 2013-06-27 2020-02-04 Roche Innovation Ct Copenhagen As Oligómeros antissentido e conjugados dirigidos para pcsk9
JP6429264B2 (ja) * 2013-11-12 2018-11-28 学校法人東京理科大学 ボラノホスフェート化合物、及び核酸オリゴマー
CA2975223C (en) * 2015-01-30 2021-08-24 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20190055550A1 (en) * 2015-08-24 2019-02-21 Roche Innovation Center Copenhagen A/S LNA-G Process
JP6973073B2 (ja) * 2015-11-06 2021-11-24 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR101841350B1 (ko) * 2016-07-05 2018-03-22 한양대학교 산학협력단 이중 플라스미드 벡터를 포함하는 지방세포 표적 비바이러스성 유전자 전달 복합체
EP3491001A1 (de) * 2016-07-27 2019-06-05 Roche Innovation Center Copenhagen A/S 5's-lna-nukleotide und oligonukleotide
EP4056701A1 (de) * 2016-08-12 2022-09-14 Nexuspiral Inc. Genomeditierungsverfahren
MX2021001284A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos al musculo y sus usos para el tratamiento de distrofia muscular facioescapulohumeral.
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248670A (en) † 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
AU3096800A (en) 1998-10-26 2000-05-15 Intervu, Inc. Audience management for interactive network events
CA2368135C (en) 1999-03-18 2010-06-08 Exiqon A/S Xylo-lna analogues
IL145496A0 (en) 1999-03-24 2002-06-30 Exiqon As Improved synthesis of [2.2.1] bicyclo nucleosides
JP2002543214A (ja) 1999-05-04 2002-12-17 エクシコン エ／エス Ｌ−リボ−ｌｎａ類縁体
US20020068709A1 (en) * 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides
WO2002028875A2 (en) 2000-10-04 2002-04-11 Cureon A/S Improved synthesis of purine locked nucleic acid analogues
AU2002317437A1 (en) * 2001-05-18 2002-12-03 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
JP4402454B2 (ja) 2001-07-12 2010-01-20 サンタリス ファーマ アー／エス Ｌｎａホスホラミダイトの製造法
US20030224515A1 (en) † 2002-06-04 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of sterol regulatory element-binding protein-1 expression
US20040005567A1 (en) † 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
WO2003091384A2 (en) * 2002-04-24 2003-11-06 Eirx Therapeutics Limited A role for survivin in apoptosis of myeloid cells
WO2004069991A2 (en) * 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression

Also Published As

Publication number Publication date
ES2329131T3 (es) 2009-11-23
EP1592793A2 (de) 2005-11-09
WO2004069991A3 (en) 2005-02-17
DE602004022020D1 (de) 2009-08-27
JP2010178742A (ja) 2010-08-19
JP4503590B2 (ja) 2010-07-14
JP2013066471A (ja) 2013-04-18
WO2004069991A2 (en) 2004-08-19
MXPA05008319A (es) 2006-02-28
JP2007523601A (ja) 2007-08-23
EP1592793B1 (de) 2009-07-15
EP1592793B2 (de) 2014-05-07
PT1592793E (pt) 2009-09-30
CA2515623A1 (en) 2004-08-19
AU2004209598B2 (en) 2009-08-06
AU2004209598A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
DK1592793T3 (da) Oligomeriske forbindelser for modulation af Survivin ekspression
DK2264172T3 (da) Oligomerforbindelser til modulering af HIF-1á-ekspression
HK1108454A1 (en) Modulation of survivin expression
SE0301569D0 (sv) Novel compounds
IS8348A (is) Samrunnin heteróhringasambönd
DK2377869T3 (da) Syntese af Bortezomib
IS8108A (is) Ný efnasambönd
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
DK1476162T3 (da) Kontrolleret syntese af ziprasidone
AU2003300020A8 (en) Modulation of pten expression via oligomeric compounds
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
IS8228A (is) Ný asetídínefnasambönd
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
IS8292A (is) Ný efnasambönd
DK1512324T3 (da) Fremgangsmåde til dearomatisering af materialer stammende fra soja
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
DK1578731T3 (da) Fremgangsmåde til fremstilling af pyrimidinforbindelser
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1597366T3 (da) Modulering af ekspression af insulin-lignende vækstfaktor receptor I
DK1656365T3 (da) Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin
DK1606246T3 (da) Fremgangsmåde til fremstilling af 2-cyan-3-hydroxy-N-(phenyl)but-2-enamider
DK1656340T3 (da) Fremgangsmåde til fremstilling af 1-carbamoylcykloalkylcarboxylsyreforbindelser